MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Award Announcements & Progress Reports: Federal Contracts, Grants & Cooperative Agreements
*Contractors & Awardees: BARDA
Summit Therapeutics Inc. (NASDAQ: SMMT)
Organization & Developments: Summit Therapeutics
Parents
Summit Therapeutics Inc. (NASDAQ: SMMT)
Children
*Clinical programmes target: Duchenne muscular dystrophy, a fatal genetic muscle wasting disease, and the infectious disease caused by the bacteria C. difficile.
*Strategy focuses on rare diseases and infectious diseases.
2018: Summit Tumbles 80% On Phase 2 DMD Failure, But The Stock Is Still Worth A Look_seekingalpha.com
2021: Summit Therapeutics: Whether It's A Go-Private Candidate
2022: Biotech billionaire Bob Duggan flies the white flag as Summit hunts a new owner, or partner, for sole clinical-stage effort
2022: Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
2023: Summit Therapeutics: Not For Retail Investors
2024: Could Summit Therapeutics Become the Next Merck?
2024: Summit lung cancer drug shows ‘striking’ benefit over Keytruda
2024: Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial_ seekingalpha.com
2024: Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
2024: Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market_ seekingalpha.com
2024: Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer_seekingalpha
2024: Summit's Phase 3 data back up biotech's boasts of beating Keytruda in lung cancer
2025: New Cancer Drug Shows Superior Results vs Standard Therapy in Lung Cancer
2025: Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
2025: Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)_seekingalpha.com
2025: Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release
2025: The Play On Summit Therapeutics
2026: FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data
Jumps
*Key People: Summit Therapeutics
Finance & Acquisitions: Summit Therapeutics